These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

235 related items for PubMed ID: 35355169

  • 1. Tear meniscus, corneal topographic and aberrometric changes after botulinum toxin-a injection in patients with blepharospasm and hemifacial spasm.
    Bayraktar Bilen N, Bilen Ş, Topçu Yılmaz P, Evren Kemer Ö.
    Int Ophthalmol; 2022 Aug; 42(8):2625-2632. PubMed ID: 35355169
    [Abstract] [Full Text] [Related]

  • 2. Evaluating the topographical measurements and tear function status in patients with hemifacial spasm: A comparative fellow eye study.
    Bayraktar Bilen N, Bilen S.
    Eur J Ophthalmol; 2023 Jan; 33(1):216-222. PubMed ID: 35787190
    [Abstract] [Full Text] [Related]

  • 3. Does blepharospasm effect biometric parameters and intraocular lens power calculations?
    Basol I, Ilhan HD.
    Int Ophthalmol; 2024 Aug 29; 44(1):358. PubMed ID: 39198275
    [Abstract] [Full Text] [Related]

  • 4. Corneal and Tear Film Changes After Botulinum Toxin-A in Blepharospasm or Hemifacial Spasm.
    Gunes A, Demirci S, Koyuncuoglu HR, Tok L, Tok O.
    Cornea; 2015 Aug 29; 34(8):906-10. PubMed ID: 26075455
    [Abstract] [Full Text] [Related]

  • 5. Ocular surface status in patients with hemifacial spasm under long-lasting treatment with botulinum A toxin: A comparative fellow eye study.
    Pellegrini M, Schiavi C, Taroni L, Sebastiani S, Bernabei F, Roda M, Moscardelli F, Giannaccare G.
    Indian J Ophthalmol; 2019 Sep 29; 67(9):1405-1409. PubMed ID: 31436182
    [Abstract] [Full Text] [Related]

  • 6. Influence of involuntary eyelid spasms on corneal topographic and eyelid morphometric changes in patients with hemifacial spasm.
    Osaki T, Osaki MH, Osaki TH, Hirai FE, Nallasamy N, Campos M.
    Br J Ophthalmol; 2016 Jul 29; 100(7):963-970. PubMed ID: 26541432
    [Abstract] [Full Text] [Related]

  • 7. Difference in response to botulinum toxin type A treatment between patients with benign essential blepharospasm and hemifacial spasm.
    Cannon PS, MacKenzie KR, Cook AE, Leatherbarrow B.
    Clin Exp Ophthalmol; 2010 Oct 29; 38(7):688-91. PubMed ID: 20456439
    [Abstract] [Full Text] [Related]

  • 8. Dry Eye Disease in Hemifacial Spasm Patients Treated with Botulinum Toxin Type A.
    Jariyakosol S, Uthaithammarat L, Chatwichaikul N, Kasetsuwan N, Chongpison Y.
    Clin Ophthalmol; 2021 Oct 29; 15():1775-1782. PubMed ID: 33953536
    [Abstract] [Full Text] [Related]

  • 9. Differences in Corneal Parameters Between Affected and Normal Contralateral Eyes in Patients With Hemifacial Spasm Treated With Botulinum Toxin-A: Outcomes During One Complete Treatment Cycle.
    Osaki T, Osaki MH, Osaki TH, Hirai FE, Campos M.
    Cornea; 2016 Feb 29; 35(2):220-5. PubMed ID: 26619386
    [Abstract] [Full Text] [Related]

  • 10. Increase lipid tear thickness after botulinum neurotoxin A injection in patients with blepharospasm and hemifacial spasm.
    Ho RW, Fang PC, Chao TL, Chien CC, Kuo MT.
    Sci Rep; 2018 May 30; 8(1):8367. PubMed ID: 29849166
    [Abstract] [Full Text] [Related]

  • 11. The influence of benign essential blepharospasm on dry eye disease and ocular inflammation.
    Lu R, Huang R, Li K, Zhang X, Yang H, Quan Y, Li Q.
    Am J Ophthalmol; 2014 Mar 30; 157(3):591-7.e1-2. PubMed ID: 24269849
    [Abstract] [Full Text] [Related]

  • 12.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 13. Characteristics of tear abnormalities associated with benign essential blepharospasm and amelioration by means of botulinum toxin type A treatment.
    Hosotani Y, Yokoi N, Okamoto M, Ishikawa H, Komuro A, Kato H, Mimura O, Gomi F.
    Jpn J Ophthalmol; 2020 Jan 30; 64(1):45-53. PubMed ID: 31823132
    [Abstract] [Full Text] [Related]

  • 14. Effectiveness of 0.3% Hyaluronic Acid Eye Drops for Benign Essential Blepharospasm and Hemifacial Spasm with Botulinum Toxin-induced Dry Eye.
    Poonyathalang A, Tiraset N, Rattanathamsakul N.
    Plast Reconstr Surg Glob Open; 2024 Aug 30; 12(8):e6050. PubMed ID: 39139840
    [Abstract] [Full Text] [Related]

  • 15. Effects of botulinum toxin type A on the treatment of dry eye disease and tear cytokines.
    Choi MG, Yeo JH, Kang JW, Chun YS, Lee JK, Kim JC.
    Graefes Arch Clin Exp Ophthalmol; 2019 Feb 30; 257(2):331-338. PubMed ID: 30552510
    [Abstract] [Full Text] [Related]

  • 16. [Botulinum toxin type A influence on the lacrimal function of patients with facial dystonia].
    Oliveira FC, Oliveira GC, Cariello AJ, Felberg S, Osaki MH.
    Arq Bras Oftalmol; 2010 Feb 30; 73(5):405-8. PubMed ID: 21225122
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19. Ocular surface alterations in blepharospasm patients treated with botulinum toxin A injection.
    Kocabeyoglu S, Sekeroglu HT, Mocan MC, Muz E, Irkec M, Sanac AS.
    Eur J Ophthalmol; 2014 Feb 30; 24(6):830-4. PubMed ID: 24803156
    [Abstract] [Full Text] [Related]

  • 20. [Ocular wavefront aberrations in patients with facial dystonia treated with botulinum toxin].
    Yabiku MM, Sartori Jde F, Sarraff EP, Osaki TH, Hossaka SK, Pereira CI, Freitas Wd, Osaki MH, Cariello AJ.
    Arq Bras Oftalmol; 2011 Feb 30; 74(6):414-6. PubMed ID: 22331113
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 12.